Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

AAD: Tazarotene Gel As Effective As Tretinoin Gel For Facial Acne By Ed Susman Special to DG News ANAHEIM, CA -- July 31, 2001 -- In a head-to-head comparison study, tazarotene 0.1% gel was at least as effective as tretinoin 0.025% gel in treating patients with facial acne vulgaris. "The results from this study confirm those from an identical study performed previously," said Dr. Nicholas Lowe, clinical professor of medicine at the UCLA School of Medicine, Los Angeles. "Both studies demonstrate that once-daily tazarotene 0.1% gel can achieve a significantly greater reduction in non-inflammatory lesion count than once-daily tretinoin 0.025% gel. Tazarotene 0.1% get is also at least as effective as tretinoin 0.025% gel in reducing the total inflammatory lesion count." Dr. Lowe presented his findings today (July 31) during a poster session at the summer scientific meeting of the American Academy of Dermatology, in Anaheim, California. In the multicenter, double-blind, randomized, parallel-group trial, patients 12 years or older who had mild to moderate facial acne were recruited. To be eligible for the trial, patients were required to show 10 to 60 facial inflammatory lesions; 10 to 200 non-inflammatory lesions (open and closed comedones); and no more than two facial nodular cystic lesions. In addition, patients discontinued other topical anti-acne medications for two weeks, were off systemic antibiotics for 30 days, and were off oral retinoids for two years. The subjects applied the gels once daily during the evening for up to 12 weeks. Through the course of the treatment, patients using tazarotene showed a statistically significant reduction in non-inflammatory lesions after four weeks when compared with tretinoin, and that reduction continued at week eight and at week 12. At week 12, Dr. Lowe said the patients using tazarotene had a 54 percent reduction in the lesions compared with a 27 percent reduction with tretinoin. In patients with inflammatory lesions, there was a greater reduction with tazarotene than with tretinoin (38 percent versus 14 percent, respectively) but Dr. Lowe said the differences in this category did not reach statistical significance. "Both treatments were well-tolerated," he said, "with mean scores for peeling, erythema, dryness and burning never exceeding mild levels." He said those results confirmed previous "split-face" studies. The research was funded by an unrestricted educational grant from Allegan Skin Care, of Irvine, California, the manufacturer of tazarotene. E-mail this page to a friend or colleague! To print, use this version